What is the role of complement-modulating agents in the treatment of age-related macular degeneration (AMD)?

Updated: Nov 11, 2019
  • Author: Lucia Sobrin, MD, MPH; Chief Editor: Karl S Roth, MD  more...
  • Print


On the basis of these complement-related genetic discoveries, various trials have been performed for complement-modulating agents, [30]  such as C3 inhibitor intravitreal compstatin/POT-4, anti-C5 antibody, C5 inhibitor ARC1905, antibody against complement factor D, antibody against BF, recombinant CFH, and a soluble form of complement receptor 1.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!